These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20860069)

  • 1. The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients.
    Marcolino MS; Boersma E; Clementino NC; Nunes Mdo C; Barbosa MM; Silva MH; Geleijnse ML; Ribeiro AL
    Hematol Oncol; 2011 Sep; 29(3):124-30. PubMed ID: 20860069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia.
    Marcolino MS; Ribeiro AL; Clementino NC; Nunes Mdo C; Barbosa MM; Silva MH; Bittencourt HN; Geleijnse ML; Boersma E
    Leuk Res; 2011 Mar; 35(3):317-22. PubMed ID: 20692037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome.
    Pieri L; Bosi A; Vannucchi AM
    Ann Hematol; 2010 Jul; 89(7):745-6. PubMed ID: 19953254
    [No Abstract]   [Full Text] [Related]  

  • 4. BNP as a marker of the heart failure in the treatment of imatinib mesylate.
    Park YH; Park HJ; Kim BS; Ha E; Jung KH; Yoon SH; Yim SV; Chung JH
    Cancer Lett; 2006 Nov; 243(1):16-22. PubMed ID: 16388897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
    Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
    Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
    Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
    Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
    Machaczka M; Gossart M
    Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients.
    Marcolino MS; Boersma E; Clementino NCD; Macedo AV; Marx-Neto AD; Silva MHCR; van Gelder T; Akkerhuis KM; Ribeiro AL
    Ann Oncol; 2011 Sep; 22(9):2073-2079. PubMed ID: 21310760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
    Beyazit Y; Aksu S; Kekilli M; Haznedaroglu IC; Kilickap S; Goker H
    Am J Hematol; 2005 May; 79(1):79-80. PubMed ID: 15849758
    [No Abstract]   [Full Text] [Related]  

  • 11. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib.
    Estabragh ZR; Knight K; Watmough SJ; Lane S; Vinjamuri S; Hart G; Clark RE
    Leuk Res; 2011 Jan; 35(1):49-51. PubMed ID: 21030079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.
    Zonder JA; Pemberton P; Brandt H; Mohamed AN; Schiffer CA
    Clin Cancer Res; 2003 Jun; 9(6):2092-7. PubMed ID: 12796373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.
    Rastogi MV; Stork L; Druker B; Blasdel C; Nguyen T; Boston BA
    Pediatr Blood Cancer; 2012 Nov; 59(5):840-5. PubMed ID: 22378641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity.
    Perik PJ; Rikhof B; de Jong FA; Verweij J; Gietema JA; van der Graaf WT
    Ann Oncol; 2008 Feb; 19(2):359-61. PubMed ID: 17962203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia.
    Salie R; Silver RT
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):331-5. PubMed ID: 21030345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients.
    Dora JM; Leie MA; Netto B; Fogliatto LM; Silla L; Torres F; Maia AL
    Eur J Endocrinol; 2008 May; 158(5):771-2. PubMed ID: 18426838
    [No Abstract]   [Full Text] [Related]  

  • 19. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
    Voglová J; Maisnar V; Beránek M; Chrobák L
    Vnitr Lek; 2006 Sep; 52(9):819-22. PubMed ID: 17091608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.